Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 3/20 | 0.37 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.35 |
| ▸ | TTR known ✓ | P02766 | 1/20 | 0.33 |
| ▸ | DPP4 known ✓ | P27487 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.45 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | MGAM | O43451 | 1/20 | 0.37 |
| ▸ | SI | P14410 | 1/20 | 0.37 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.37 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1145438 | 1.00 | NPSR1 (0.59) | NPSR1ALOX15ALDH1A1HCAR2TRPA1 | |
| SCHEMBL2184545 | 0.98 | NPSR1 (0.61) | NPSR1ALOX15ALDH1A1HCAR2TRPA1 | |
| SCHEMBL12602888 | 0.98 | NPSR1 (0.61) | NPSR1ALOX15ALDH1A1HCAR2TRPA1 | |
| SCHEMBL2184541 | 0.98 | NPSR1 (0.61) | NPSR1ALOX15ALDH1A1HCAR2TRPA1 | |
| SCHEMBL11819022 | 0.85 | NPSR1 (0.53) | NPSR1ALOX15ALDH1A1HCAR2TRPA1 | |
| SCHEMBL11819025 | 0.85 | NPSR1 (0.53) | NPSR1ALOX15ALDH1A1HCAR2TRPA1 | |
| SCHEMBL11816105 | 0.85 | NPSR1 (0.48) | NPSR1ALOX15ALDH1A1HCAR2TRPA1 | |
| SCHEMBL11816114 | 0.85 | NPSR1 (0.48) | NPSR1ALOX15ALDH1A1HCAR2TRPA1 | |
| SCHEMBL11740838 | 0.84 | NPSR1 (0.47) | NPSR1ALOX15ALDH1A1HCAR2TRPA1 | |
| SCHEMBL11623721 | 0.84 | NPSR1 (0.47) | NPSR1ALOX15ALDH1A1HCAR2TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1747059-A1 | PERVAPORATION COMPOSITE MEMBRANES | McMaster University (CA) | 2007-01-31 | — | — | EP | claimed |
| US-20060000778-A1 | high-performance membrane designed for the selective removal of a polar fluid (water) from less polar fluids (organic solvents), by a pervaporation using a composite membrane contaiing ultrafiltration membrane as support ( e.g. cellulose acetate) and a crosslinked copolymer of anionic, cationic monomers | MCMASTER UNIVERSITY (CA) | 2006-01-05 | — | — | US | claimed |
| WO-2005102503-A1 | PERVAPORATION COMPOSITE MEMBRANES | MCMASTER UNIVERSITY (CA) | 2005-11-03 | — | — | WO | claimed |
| US-9732066-B2 | Heterocyclic derivative and pharmaceutical drug | NIPPON SHINY AKU CO., LTD. (JP) | 2017-08-15 | — | — | US | disclosed |
| EP-2226192-B1 | DRYING SUBSTANCES, PREPARATION AND USE THEREOF | ORIDION MEDICAL 1987 LTD (IL) | 2016-08-31 | — | — | EP | disclosed |
| EP-2563126-B1 | HETEROCYCLIC QUINOLIZINE DERIVED M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2016-05-11 | — | — | EP | disclosed |
| EP-2226116-B1 | Drying tube, preparation and use thereof | ORIDION MEDICAL 1987 LTD (IL) | 2016-04-20 | — | — | EP | disclosed |
| CN-103857657-B | Hete rocyclic derivatives and medicine | NIPPON SHINYAKU CO.,LTD. (JP) | 2016-04-20 | — | — | CN | disclosed |
| US-20160046612-A1 | Heterocyclic Derivative and Pharmaceutical Drug | NIPPON SHINYAKU CO., LTD. (JP) | 2016-02-18 | — | — | US | disclosed |
| US-9216968-B2 | Heterocyclic derivative and pharmaceutical drug | NIPPON SHINYAKU CO., LTD. (JP) | 2015-12-22 | — | — | US | disclosed |
| EP-2746265-B1 | HETEROCYCLIC DERIVATIVE AS MICROSOMAL PROSTAGLANDIN E SYNTHASE (mPGEs) INHIBITOR | NIPPON SHINYAKU CO LTD (JP) | 2015-11-18 | — | — | EP | disclosed |
| US-20060000778-A1 | high-performance membrane designed for the selective removal of a polar fluid (water) from less polar fluids (organic solvents), by a pervaporation using a composite membrane contaiing ultrafiltration membrane as support ( e.g. cellulose acetate) and a crosslinked copolymer of anionic, cationic monomers | MCMASTER UNIVERSITY (CA) | 2006-01-05 | — | — | US | disclosed |
| WO-2005102503-A1 | PERVAPORATION COMPOSITE MEMBRANES | MCMASTER UNIVERSITY (CA) | 2005-11-03 | — | — | WO | disclosed |
| WO-2005061514-A1 | PYRANO-QUINOLINES, PYRANO-QUINOLINONES, COMBINATIONS THEREOF, PHOTOCHROMIC COMPOSITIONS AND ARTICLES | TRANSITIONS OPTICAL, INC. (US) | 2005-07-07 | — | — | WO | disclosed |
| US-20050127336-A1 | Pyrano-quinolines, pyrano-quinolinones, combinations thereof, photochromic compositions and articles | TRANSITIONS OPTICAL INC. | 2005-06-16 | — | — | US | disclosed |
| EP-0839144-B1 | PIPERAZINE DERIVATIVES AS THERAPEUTIC AGENTS | KNOLL GMBH (DE) | 2001-09-19 | — | — | EP | disclosed |
| WO-1999040092-A1 | OXO-DIPYRIDOIMIDAZOLE-CARBOXAMIDES: GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1999-08-12 | — | — | WO | disclosed |
| EP-0839144-A1 | PIPERAZINE DERIVATIVES AS THERAPEUTIC AGENTS | Knoll AG (DE) | 1998-05-06 | — | — | EP | disclosed |
| WO-1997003067-A1 | PIPERAZINE DERIVATIVES AS THERAPEUTIC AGENTS | KNOLL AKTIENGESELLSCHAFT (DE) | 1997-01-30 | — | — | WO | disclosed |
| US-4549019-A | Pyrimidinecarbamate derivatives as intermediates | HOFFMANN-LA ROCHE INC. (US) | 1985-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160046612-A1 | Heterocyclic Derivative and Pharmaceutical Drug | PTGES, PTGER1, PTGS1 | GAA 2700/4885CA2 546/4885TTR 3740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.